Liver Metastasis Clinical Trial
Official title:
Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis
Stage I：preoperative therapy
- Capecitabine plus oxaliplatin with herceptin is superior to surgery alone for patients
with potentially resectable HER-2 positive gastric cancer with liver metastasis; Stage
II: Perioperative therapy
- Perioperative Capecitabine plus oxaliplatin with herceptin is superior to adjuvant
Capecitabine plus oxaliplatin alone for patients with potentially resectable HER-2
positive gastric cancer with liver metastasis;
The investigators assessed whether the addition of a perioperative regimen of XELOX regimen with herceptin to improves R0 resection rate and survival among patients with potentially resectable HER-2 positive gastric cancer with liver metastasis. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05524155 -
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
|
Phase 2 | |
| Recruiting |
NCT02632201 -
Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT01715402 -
Optimization of Health Expenditure in Liver Surgery
|
N/A | |
| Recruiting |
NCT01035385 -
Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)
|
Phase 3 | |
| Recruiting |
NCT05098847 -
Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT02651090 -
Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI
|
Phase 3 | |
| Withdrawn |
NCT01775280 -
Response of Hepatic Tumors to Radioembolization
|
Phase 2 | |
| Completed |
NCT00068068 -
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
|
Phase 2 | |
| Terminated |
NCT02453490 -
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
|
Phase 3 | |
| Recruiting |
NCT04622423 -
Advanced Therapies for Liver Metastases
|
||
| Completed |
NCT00892424 -
Sorafenib-RT Treatment for Liver Metastasis (SLIM)
|
Phase 1/Phase 2 | |
| Completed |
NCT00028405 -
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
|
Phase 1 | |
| Completed |
NCT03801915 -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
|
Phase 2 | |
| Completed |
NCT02218801 -
A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
|
||
| Completed |
NCT01834014 -
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
|
N/A | |
| Completed |
NCT00083785 -
Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT03428477 -
EPA for Metastasis Trial 2
|
Phase 3 | |
| Completed |
NCT02316028 -
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
|
Phase 1/Phase 2 | |
| Completed |
NCT01785212 -
The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver
|
N/A | |
| Completed |
NCT03785210 -
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
|
Phase 2 |